Dipeptidyl peptidase (DPP)-4 inhibitors (DPP-4i) are currently used for the management of T2D, as they prevent the degradation of endogenous incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic peptide [GIP]), leading to meal-induced insulin secretion. This evidence concerns the gene GIP and type 2 diabetes mellitus.